Projects
Drugs & Driving: integrating epidemiological and experimental data on drug induced driver impairment and crash risk Ghent University
The present research collaboration aims to integrate epidemiological data and experimental data on drug induced driver impairment and crash risk. Epidemiological data on drug induced crash risk or culpability risk has been collected by Prof Verstraete as part of a European research effort (DRUID) and will be provided by Prof Verstraete for additional, explorative analysis. Experimental data on drug effects on driver impairment will be ...
Development of a biorelevant in vitro drug release method for long-acting injectable nanosuspensions of poorly soluble drugs. KU Leuven
Sustained parenteral drug delivery can significantly improve treatment adherence and, hence, the clinical outcome of various chronic illnesses, such as HIV and schizophrenia to name just a few. Long-acting injectable (LAI) nano-/microsuspensions constitute an attractive formulation strategy for poorly soluble drugs and have been the subject of increasing research (Chapter 1). These LAI formulations possess unique features offering ...
CD3 - the Centre for Drug Design and Discovery – discovering new drugs based on innovative research KU Leuven
Het Centre for Drug Design and Discovery (CD3) is een drug discovery centrum en investeringsfonds dat focust op de transformatie van innovatief basisonderzoek naar klinische toepassing. CD3’s activiteiten zijn steeds gebaseerd op een samenwerkingsmodel met academische onderzoeksgroepen en biotech/pharma partners om samen nieuwe geneesmiddelen te ontwikkelen. Het ervaren drug discovery team van CD3 investeert in bedrijven en in vroege drug ...
Drug resistance in MYC/MYCN driven tumor entities as a consequence of replicative stress induced DNA damage response: an entry point for synthetic lethal drugs Ghent University
Chemoresistance is a major impediment to succesful treatment of a growing number of cancer entitites. Circumventing this phenomenon demands highly selective and efficient targeting of cancer-specific pathways. We have recently discovered that MYC(N)-driven tumors show strong upregulation of genes involved in replicative stress-induced DNA damage repair. We thereby identified FOXM 1 as a central regulator. Our data suggest that FOXM1 driven ...
Drug resistance in MYC/MYCN driven tumor entities as a consequence of replicative stress induced DNA damage response : an entry point for synthetic lethal drugs. University of Antwerp
Experimental evolution in Candida biofilms: does drug tolerance facilitate drug resistance development in fungi?Experimental evolution in Candida biofilms: does drug tolerance facilitate drug resistance development in fungi? KU Leuven
Invasive fungal infections pose a profound and growing public health threat with treatment failure and mortality estimates often surpassing 50%. Only three major antifungal drug classes are available to treat lethal fungemia and the incidence of resistance to these drugs has risen significantly in recent years. Moreover, multidrug resistant (MDR) ‘superbugs’ like Candida auris have emerged. Despite these alarming concerns, fungal infections ...
Estimating the size of drug markets in a selection of European cities using data drived from the analysis of drug and drug metabolite residues in municipal waste water. University of Antwerp
The first hurdle in oral drug disposition: exploring the impact of gastric residence on drug behaviour in man KU Leuven
Reducing the late-stage attrition of potential drug candidates can be considered one of the major challenges for the oral drug development process to date. One of the factors potentially leading to the attrition of a drug candidate at the clinical stages of the drug development process is formulation failure. Formulation failure can be attributed to the fact that selecting the appropriate formulation strategy often occurs on a trial-and-error ...
Performance of supersaturating drug delivery systems in real-life conditions: in vivo characterisation of gastric drug behavior supporting the development of predictive tools. KU Leuven
Once marketed, drugs may suffer from suboptimal performance as they are often taken with meals and/or beverages not accounted for during clinical trials. Any ingested formulation will initially reside in the stomach where exposure to a variety of internal (e.g. pH and motility) and external factors (e.g. co-administration of beverages and foods) potentially influences intragastric formulation disintegration and drug dissolution. As this ...